Imexpharm Corporation (HOSE:IMP)
Vietnam · Delayed Price · Currency is VND 35,100
+100 (0.29%)
At close: Nov 3, 2026
Imexpharm Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,292,869 | 2,441,085 | 2,205,120 | 1,994,037 | 1,643,707 | 1,266,597 | |
Revenue Growth | -6.50% | 10.70% | 10.59% | 21.31% | 29.77% | -7.51% |
Cost of Revenue | 1,188,097 | 1,282,008 | 1,181,634 | 1,010,064 | 824,152 | 669,657 |
Gross Profit | 1,104,773 | 1,159,077 | 1,023,486 | 983,973 | 819,555 | 596,940 |
Selling, General & Admin | 641,436 | 696,642 | 608,328 | 602,926 | 523,055 | 362,868 |
Operating Expenses | 641,436 | 696,642 | 608,328 | 602,926 | 523,055 | 362,868 |
Operating Income | 463,337 | 462,435 | 415,158 | 381,047 | 296,500 | 234,072 |
Interest Expense | -12,101 | -16,501 | -3,489 | -6,036 | -3,795 | -5,496 |
Interest & Investment Income | 24,195 | 19,790 | 7,929 | 19,877 | 19,853 | 12,364 |
Currency Exchange Gain (Loss) | 1,914 | 1,698 | 2,410 | 2,613 | -2,053 | 3,436 |
Other Non Operating Income (Expenses) | -16,210 | -21,175 | -19,654 | -20,221 | -19,448 | -9,413 |
EBT Excluding Unusual Items | 461,135 | 446,248 | 402,354 | 377,279 | 291,059 | 234,963 |
Gain (Loss) on Sale of Investments | - | - | 1,839 | -6.02 | 345.28 | 3,896 |
Gain (Loss) on Sale of Assets | 146.6 | - | - | - | - | - |
Pretax Income | 461,281 | 446,248 | 404,193 | 377,273 | 291,404 | 238,859 |
Income Tax Expense | 93,881 | 97,110 | 83,331 | 77,717 | 67,864 | 49,764 |
Net Income | 367,400 | 349,138 | 320,862 | 299,556 | 223,540 | 189,095 |
Preferred Dividends & Other Adjustments | 46,741 | 44,749 | 45,000 | 21,778 | 39,697 | 15,582 |
Net Income to Common | 320,659 | 304,389 | 275,862 | 277,778 | 183,844 | 173,513 |
Net Income Growth | 0.54% | 10.34% | -0.69% | 51.09% | 5.95% | -3.42% |
Shares Outstanding (Basic) | 154 | 154 | 154 | 154 | 154 | 154 |
Shares Outstanding (Diluted) | 154 | 154 | 154 | 154 | 154 | 154 |
Shares Change | - | - | - | -0.00% | -0.00% | 2.92% |
EPS (Basic) | 2082.08 | 1976.44 | 1791.21 | 1803.65 | 1193.71 | 1126.63 |
EPS (Diluted) | 2082.08 | 1976.44 | 1791.21 | 1803.65 | 1193.64 | 1126.63 |
EPS Growth | 0.54% | 10.34% | -0.69% | 51.11% | 5.95% | -6.15% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 350,607 | 27,292 | 119,497 | -103,064 | 279,250 | 182,024 |
Free Cash Flow Per Share | 2276.54 | 177.21 | 775.91 | -669.21 | 1813.19 | 1181.89 |
Dividend Per Share | - | - | 500.000 | 454.546 | 432.901 | 649.351 |
Dividend Growth | - | - | 10.00% | 5.00% | -33.33% | 0% |
Gross Margin | 48.18% | 47.48% | 46.41% | 49.35% | 49.86% | 47.13% |
Operating Margin | 20.21% | 18.94% | 18.83% | 19.11% | 18.04% | 18.48% |
Profit Margin | 13.98% | 12.47% | 12.51% | 13.93% | 11.19% | 13.70% |
Free Cash Flow Margin | 15.29% | 1.12% | 5.42% | -5.17% | 16.99% | 14.37% |
EBITDA | 563,730 | 565,411 | 520,794 | 463,689 | 356,886 | 294,484 |
EBITDA Margin | 24.59% | 23.16% | 23.62% | 23.25% | 21.71% | 23.25% |
D&A For EBITDA | 100,393 | 102,976 | 105,636 | 82,642 | 60,386 | 60,412 |
EBIT | 463,337 | 462,435 | 415,158 | 381,047 | 296,500 | 234,072 |
EBIT Margin | 20.21% | 18.94% | 18.83% | 19.11% | 18.04% | 18.48% |
Effective Tax Rate | 20.35% | 21.76% | 20.62% | 20.60% | 23.29% | 20.83% |
Revenue as Reported | 2,292,869 | 2,441,085 | 2,205,120 | 1,994,037 | 1,643,707 | 1,266,597 |
Advertising Expenses | - | 161,446 | 170,332 | 175,099 | 123,665 | 110,468 |